These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 39239275

  • 1. Efficacy and safety of PD-1 inhibitors plus anti-angiogenesis tyrosine kinase inhibitors with or without transarterial chemo(embolization) for unresectable hepatocellular carcinoma: a meta-analysis.
    Chen Y, Jia L, Li Y, Cui W, Wang J, Zhang C, Bian C, Luo T.
    Front Oncol; 2024; 14():1364345. PubMed ID: 39239275
    [Abstract] [Full Text] [Related]

  • 2. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
    Ke Q, Xin F, Fang H, Zeng Y, Wang L, Liu J.
    Front Immunol; 2022; 13():913464. PubMed ID: 35677059
    [Abstract] [Full Text] [Related]

  • 3. Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study.
    Chen Y, Jia L, Li Y, Cui W, Wang J, Zhang C, Bian C, Wang Z, Lin D, Luo T.
    Ann Surg Oncol; 2024 Nov; 31(12):7860-7869. PubMed ID: 39090499
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis.
    Chen Y, Jia L, Li Y, Cui W, Wang J, Zhang C, Bian C, Luo T.
    Front Immunol; 2024 Nov; 15():1466113. PubMed ID: 39281676
    [Abstract] [Full Text] [Related]

  • 5. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
    Yu B, Zhang N, Feng Y, Zhang Y, Zhang T, Wang L.
    J Hepatocell Carcinoma; 2023 Nov; 10():1735-1748. PubMed ID: 37822726
    [Abstract] [Full Text] [Related]

  • 6. Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
    Duan R, Gong F, Wang Y, Huang C, Wu J, Hu L, Liu M, Qiu S, Lu L, Lin Y.
    World J Surg Oncol; 2023 Mar 31; 21(1):120. PubMed ID: 37004052
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis.
    Ji J, Zhang Z, Hou Z, Qiu G, Mi S, Jin Z, Huang J.
    Clin Res Hepatol Gastroenterol; 2024 Apr 31; 48(4):102313. PubMed ID: 38453011
    [Abstract] [Full Text] [Related]

  • 8. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Kong SY, Song JJ, Jin YQ, Deng MJ, Yan JX.
    Acta Clin Belg; 2023 Apr 31; 78(2):171-179. PubMed ID: 35587164
    [Abstract] [Full Text] [Related]

  • 9. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
    Liu JN, Li JJ, Yan S, Zhang GN, Yi PS.
    Front Oncol; 2023 Apr 31; 13():1074793. PubMed ID: 36910612
    [Abstract] [Full Text] [Related]

  • 10. Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma.
    Pang B, Zuo B, Huang L, You X, Liu T, Hao J, Yuan C, Yang C, Yee Lau W, Zhang Y.
    Int Immunopharmacol; 2024 Aug 20; 137():112492. PubMed ID: 38906005
    [Abstract] [Full Text] [Related]

  • 11. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis.
    Si T, Huang Z, Khorsandi SE, Ma Y, Heaton N.
    Front Bioeng Biotechnol; 2022 Aug 20; 10():1010824. PubMed ID: 36237208
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of transarterial therapy combined with first-line tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a network meta-analysis.
    Hu L, Lin J, Shi X, Wang A.
    World J Surg Oncol; 2023 Jul 21; 21(1):208. PubMed ID: 37475030
    [Abstract] [Full Text] [Related]

  • 13. Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Tan Z, Zhang J, Xu L, Wang H, Mao X, Zou R, Wang Q, Han Z, Di Z, Wu D.
    PLoS One; 2023 Jul 21; 18(10):e0290644. PubMed ID: 37844117
    [Abstract] [Full Text] [Related]

  • 14. Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis.
    Cao YZ, Zheng GL, Zhang TQ, Shao HY, Pan JY, Huang ZL, Zuo MX.
    World J Gastroenterol; 2024 Jan 28; 30(4):318-331. PubMed ID: 38313229
    [Abstract] [Full Text] [Related]

  • 15. Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study.
    Huang Z, Chen T, Li W, He W, Liu S, Wu Z, Li B, Yuan Y, Qiu J.
    Int Immunopharmacol; 2024 Sep 30; 139():112711. PubMed ID: 39029233
    [Abstract] [Full Text] [Related]

  • 16. The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review.
    Yuanren G, Yin L, Liu R, Cui Y.
    Front Oncol; 2023 Sep 30; 13():1054072. PubMed ID: 36969065
    [Abstract] [Full Text] [Related]

  • 17. The safety and efficacy of TACE combined with HAIC, PD-1 inhibitors, and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a retrospective study.
    Huang Z, Wu Z, Zhang L, Yan L, Jiang H, Ai J.
    Front Oncol; 2024 Sep 30; 14():1298122. PubMed ID: 38318115
    [Abstract] [Full Text] [Related]

  • 18. Immune-targeted therapy with transarterial chemo(embolization) for unresectable HCC: a systematic review and meta-analysis.
    Fang H, Ke Q, Wu S, Tu Q, Wang L.
    Front Immunol; 2024 Sep 30; 15():1421520. PubMed ID: 39156893
    [Abstract] [Full Text] [Related]

  • 19. Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma.
    Chen B, Dai H, Yang J, Zhang G, Wen C, Xiang X, Lin R, Huang Y.
    Curr Cancer Drug Targets; 2023 Sep 30; 23(7):564-571. PubMed ID: 36790005
    [Abstract] [Full Text] [Related]

  • 20. Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma.
    Long T, Yang Z, Zeng H, Wu W, Hu Z, Yang Z, Hu D, Zhou Z, Chen M, Zhang Y.
    J Hepatocell Carcinoma; 2023 Sep 30; 10():1849-1859. PubMed ID: 37881221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.